Evidence map›Paper›PMID 41885233›Full record

ReviewCurrent opinion in psychiatry2026

Surveillance of emerging drug trends: utilizing the National Drug Early Warning System.

Linda B Cottler, Joseph J Palamar

Abstract readReview
In one paragraph

Review in Current opinion in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Linda B CottlerDepartment of Epidemiology, College of Public Health and Health Professions, College of Medicine, University of Florida, Gainesville, Florida.
Joseph J PalamarDepartment of Population Health, NYU Grossman School of Medicine, New York, NY, USA.

Funding

National Drug Early Warning System (NDEWS) COVID-19 SupplementU01DA051126 · NIDA · UNIVERSITY OF FLORIDA · PI Linda B. Cottler, Joseph J Palamar · 2020 to 2026
$6.3M
UF Substance Abuse Training Center in Public HealthT32DA035167 · NIDA · UNIVERSITY OF FLORIDA · PI Linda B. Cottler · 2014 to 2026
$4.8M
NIDA NIH HHS T32 DA035167NIDA NIH HHS U01 DA051126
6 · The paper itself

Abstract

purpose of reviewThe U.S. drug landscape is rapidly shifting necessitating early warning surveillance of emerging drug threats. We describe one such surveillance effort from the United States: the National Drug Early Warning System (NDEWS). RECENT

findingsNDEWS monitors drug indicators with a particular focus on trends in new psychoactive substances (NPS) and emerging adulterants. NDEWS has five major goals: develop a collaboration network, including people with lived experience, initiate methods that deliver the freshest data on drug trends, integrate data from sources to better understand signals, disseminate findings widely, and train the next generation of surveillance scientists. NDEWS collects primary data using venue-based methods (Rapid Street Reporting), Web Monitoring, and 911 (Emergency Medical Service) data, and utilizes secondary data on drug seizures and poisonings. Information is shared bidirectionally with our 16 Sentinel Sites, our Community-Based Health Expert network, and our informal networks which include medical examiners, toxicologists, funeral directors, reporters, and community overdose response workers. SUMMARY: Surveillance of emerging drug trends is increasingly important around the world as patterns of drug use continue to shift. With a focus on NPS and nonlagged data strategies, NDEWS warns communities at risk to prevent serious consequences and death.

Indexed as

Illicit DrugsPopulation SurveillancePsychotropic DrugsSubstance-Related DisordersHumansUnited StatesIllicit DrugsPsychotropic Drugsdrug monitoringdrug surveillanceepidemiologynew psychoactive substances

Identifiers

PMID41885233
PMCPMC13025665

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.